Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection
Patients must not have a history of chronic or active hepatitis B or C infection; patients must have negative hepatitis B and C serologies performed within days prior to registration
Known or suspected chronic active Epstein-Barr virus (EBV) infection, acute or chronic hepatitis C virus (HCV) infection
Participants with active chronic or acute hepatitis C or B infection
Active or chronic hepatitis B or C infection\r\n* Previously infected with evidence of immunity and no evidence of active hepatitis is not an exclusion criterion
Participants with known active or chronic infection with hepatitis B or C.
Active hepatitis B virus (HBV) infection (chronic or acute)
Patients with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Subjects with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
Acute or chronic Hepatitis C virus (HCV) infection
Chronic, active, or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier
Active ongoing infection requiring therapy; patients with known chronic hepatitis C infection will be allowed if antiviral therapy is not in use; patients with evidence of chronic hepatitis B infection as evidenced by hepatitis B surface antigen positivity and/or evidence of hepatitis B circulating deoxyribonucleic acid (DNA) are required to receive viral prophylaxis while on treatment with entecavir or tenofavir per institutional guidelines; hepatitis viral load studies will be followed as described in protocol
Known history of human immunodeficiency virus (HIV) seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment; patients receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection or chronic obstructive pulmonary disease) are eligible
Known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Positive test results for chronic hepatitis B and hepatitis C infection
Known or chronic hepatitis C and/or B infection
Chronic infection with hepatitis B or hepatitis C virus
Active or chronic hepatitis B infection
Subject has a chronic or acute hepatitis C infection; subject with an old infection that has cleared may be included
Subject has a chronic or acute hepatitis B infection; subject with an old infection that has cleared may be included
Chronic hepatitis infection, including B and C
Known active or chronic hepatitis B or C infection
Patients with history of active hepatitis B or C infection or chronic hepatitis with Child Pugh B or C hepatic dysfunction
Presence of any other active or suspected acute or chronic uncontrolled infection or known symptomatic active hepatitis B or C
Acute or chronic hepatitis B or C infection
Presence of an active acute or chronic infection including: a urinary tract infection as determined by their physician, HIV (as determined by enzyme-linked immunosorbent assay [ELISA] and confirmed by Western blot) or viral hepatitis (as determined by hepatitis B surface antigen [HBsAg] and hepatitis C serology)
Chronic hepatitis B or hepatitis C infection
Patients with a history of hepatitis B with persistent infection.
Prior, current, or chronic hepatitis B or hepatitis C infection
Patients with non-hepatocellular carcinoma must not have acute or chronic hepatitis B or hepatitis C infection
Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Serologic status reflecting active hepatitis B or C infection.
Subjects with a history of chronic or acute hepatitis C or B infection.
History of chronic hepatitis B or C infection
Patients with known acute or chronic hepatitis B or hepatitis C infection are ineligible
Chronic active untreated hepatitis B or C infection
Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection
Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection
Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection
Chronic hepatitis infection, including B and C
Chronic hepatitis infection, including B and C
Hepatitis C infection; patient may have hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and LAI
Known history of HIV seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment
Active or chronic infection of hepatitis B virus or hepatitis C
No active or chronic infection with hepatitis C
Negative screening tests for hepatitis B and hepatitis C; patients with positive results that do not indicate true active or chronic infection may enroll after discussion and consensus agreement by the treating physician and principal investigator
Diagnosis of infection with HIV or chronic infection with hepatitis B or C
Known disease or history of active or chronic hepatitis C and/or B infection
Chronic active or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier
Known acute or chronic hepatitis B or hepatitis C infection
Positive test results for chronic hepatitis B infection and hepatitis C virus (HCV)
Acute or chronic active hepatitis B or C infection, or other serious chronic infection requiring ongoing treatment
Active or chronic hepatitis C and/or B infection
For gastric/GEJ and NSCLC participants, has chronic hepatitis B or hepatitis C infection. (For HCC participants, those with chronic hepatitis B virus [HBV] infection with a negative HBV deoxyribonucleic acid [DNA] test and who are on antiviral therapy, and those with chronic hepatitis C virus [HCV] infection are eligible)
No active or chronic hepatitis C and/or B infection
Negative hepatitis B serologic tests; if positive results are not indicative of active or chronic infection, the subjects can enter the study at the investigators discretion
Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier
COHORT B: No active or chronic infection with HIV, hepatitis B or hepatitis C (negative screening tests required)
Prior, current, or chronic hepatitis B or hepatitis C infection
Patients with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
Active hepatitis B or hepatitis C, or laboratory evidence for a chronic infection.
Subject has a chronic or acute hepatitis C infection
Subject has a chronic or acute hepatitis B infection
Subjects with known active hepatitis (i.e., Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infection
Hepatitis C infection; patient may have a hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and lead associate investigator
History of HIV infection or active hepatitis B (chronic or acute) or hepatitis C infection
Acute or chronic hepatitis B (HBV) or hepatitis C (HCV) infection requiring concomitant treatment prohibited by this protocol (i.e.immunosuppressive therapy)
Known history of active or chronic hepatitis C and/or B infection
Prior, current, or chronic hepatitis B or hepatitis C infection
Chronic active or acute viral hepatitis A, B, or C infection or hepatitis B or C carrier
Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C)
Positive test results for chronic hepatitis BsAg infection.
Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier
Known active or chronic hepatitis B or hepatitis C infection
Chronic active hepatitis B or C infection
History of HIV infection or acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines
Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier
Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection
Chronic hepatitis B or C infection.
Prior, current or chronic hepatitis B or hepatitis C infection
Chronic hepatitis B or C infection
Known acute or chronic hepatitis B or hepatitis C infection as determined by serologic tests
Known acute or chronic hepatitis B or hepatitis C infection as determined by serologic tests
Hepatitis C infection; patient may have hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and protocol chairperson
Chronic, active, or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier
Active chronic hepatitis C and/or B infection
Known active or chronic hepatitis B or hepatitis C infection
Absence of known HIV infection, chronic hepatitis B, or hepatitis C infection; absence of any other serious medical condition which could interfere with oral medication intake